Environmental or self-antigens and homotypic interactions cause BCR and Toll-like receptor (TLR) signaling, amplifying the reaction of CLL cells to other indicators from the microenvironment and increasing the activation of anti-apoptotic and proliferation pathways. Duvelisib was the 2nd PI3K inhibitor authorised because of the FDA, also dependant on a stage https://marlonu742mwc9.wikipowell.com/user